Penumbra Inc (PEN)

$335.06 -1.05 (-0.31%)
Market Cap 13.21B
Revenue (ttm) 1.40B
Net Income (ttm) 177.69M
EPS (ttm) N/A
PE Ratio 88.44
Forward PE 66.88
Profit Margin 12.66%
Debt to Equity Ratio 0.00
Volume 256,517
Avg Vol 1,113,252
Day's Range N/A - N/A
Shares Out 39.24M
Stochastic %K 13%
Beta 0.81
Analysts Sell
Price Target $362.13

Company Profile

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra d...

Industry: Medical Devices
Sector: Healthcare
Phone: 510 748 3200
Address:
One Penumbra Place, Alameda, United States
smartkarma
smartkarma Mar. 6 at 8:03 PM
$PEN | Penumbra: STORM-PE Clinical Momentum & Physician Adoption—The Engine Behind Its Procedure Growth! "Penumbra, a company engaged in the innovative medical devices sector, has recently reported its financial performance for the third quarter of..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/penumbra-storm-pe-clinical-momentum-physician-adoption-the-engine-behind-its-procedure-growth
0 · Reply
ZacksResearch
ZacksResearch Mar. 2 at 1:18 PM
$PEN gets acquired! What does this mean for investors? 🤔 PEN announced a definitive agreement to be acquired by Boston Scientific for $374 per share, valuing the company at approximately $14.5 billion. The deal, subject to shareholder approval, is expected to close in 2026. See what this acquisition means for Penumbra's stockholders 👉 https://www.zacks.com/stock/news/2877227/pen-stock-up-following-q4-earnings-revenue-beat-margins-rise?cid=sm-stocktwits-2-2877227-body-35674&ADID=SYND_STOCKTWITS_TWEET_2_2877227_BODY_35674
0 · Reply
ZacksResearch
ZacksResearch Mar. 2 at 12:18 PM
$PEN pops after a clean Q4 beat — and margins are moving higher. 🚀 The company topped both earnings and revenue expectations in Q4, while also posting rising margins — a combo that signals improving operational strength, not just top-line noise. Beats + margin expansion? That’s how trends change. Get the full breakdown on what’s driving the move 👉 https://www.zacks.com/stock/news/2877227/pen-stock-up-following-q4-earnings-revenue-beat-margins-rise?cid=sm-stocktwits-2-2877227-teaser-35673&ADID=SYND_STOCKTWITS_TWEET_2_2877227_TEASER_35673
0 · Reply
cvmoney
cvmoney Feb. 27 at 9:51 PM
$PEN I want $370 by 3/20
0 · Reply
erevnon
erevnon Feb. 26 at 5:15 PM
Evercore ISI Group maintains Penumbra $PEN at Outperform and raises the price target from $340 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Estimize
Estimize Feb. 25 at 6:45 PM
$PEN reported 1.18 EPS and 385.39 revenue for Q4. http://www.estimize.com/intro/pen?chart=historical&metric_name=eps&utm_content=PEN&utm_me
0 · Reply
IN0V8
IN0V8 Feb. 20 at 9:27 PM
$PEN Canaccord Genuity cuts to hold from buy Canaccord Genuity raises target price to $374 from $359
0 · Reply
Subox
Subox Feb. 12 at 6:53 AM
$PEN $PEN drops like this are uncommon after an acquisition announce, does anyone know if one of the shareholders is maybe voting against the deal? A 15% premium is definitely not normal
0 · Reply
yaydeezie
yaydeezie Feb. 9 at 8:36 PM
$PEN Does anyone know what’s next for shareholders of $PEN in the $BSX acquisition? “Deal Structure and Shareholder Consideration Under the terms of the agreement, Penumbra shareholders will receive $374 per share, based on the volume-weighted average price of Boston Scientific stock over the ten trading days ending January 13. Shareholders may elect to receive either $374 in cash or 3.8721 shares of Boston Scientific stock, subject to proration.” https://news.bostonscientific.com/2026-01-15-Boston-Scientific-announces-agreement-to-acquire-Penumbra,-Inc
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 5 at 2:50 AM
$PEN Share Price: $339.88 Contract Selected: Jul 17, 2026 $340 Calls Buy Zone: $8.42 – $10.40 Target Zone: $15.34 – $18.75 Potential Upside: 72% ROI Time to Expiration: 162 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on PEN
8 Stocks to Buy as Merger-Mania Takes Over

Mar 10, 2026, 12:42 PM EDT - 2 days ago

8 Stocks to Buy as Merger-Mania Takes Over

AVTR BSX EPC ITGR MXL POWI PRGO

Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 25, 2026, 1:00 PM EST - 15 days ago

Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

BSX

Allspring Growth Fund Q4 2025 Fund Performers And Detractors

Feb 12, 2026, 9:15 PM EST - 27 days ago

Allspring Growth Fund Q4 2025 Fund Performers And Detractors

ARGX BBIO COIN CRS DASH GOOG GOOGL

Boston Scientific announces results for fourth quarter and full year 2025

Feb 4, 2026, 6:30 AM EST - 5 weeks ago

Boston Scientific announces results for fourth quarter and full year 2025

BSX

Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights

Jan 27, 2026, 2:16 PM EST - 6 weeks ago

Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights

RAPT

Artisan Small Cap Fund Q4 2025 Portfolio Activity

Jan 23, 2026, 9:08 AM EST - 6 weeks ago

Artisan Small Cap Fund Q4 2025 Portfolio Activity

BRKR CLBT FLEX GH HXL INSM IRTC

Boston Scientific to buy Penumbra in $14.5B deal to expand cardiovascular reach

Jan 15, 2026, 9:11 AM EST - 2 months ago

Boston Scientific to buy Penumbra in $14.5B deal to expand cardiovascular reach

BSX

Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion.

Jan 15, 2026, 8:45 AM EST - 2 months ago

Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion.

BSX

Boston Scientific is buying Penumbra for $14.5 billion, gaining entry to ‘fast-growing' vascular segments

Jan 15, 2026, 8:11 AM EST - 2 months ago

Boston Scientific is buying Penumbra for $14.5 billion, gaining entry to ‘fast-growing' vascular segments

BSX

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock

Jan 15, 2026, 7:19 AM EST - 2 months ago

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock

BSX

Boston Scientific to buy Penumbra in deal valued at $14.5 billion

Jan 15, 2026, 7:07 AM EST - 2 months ago

Boston Scientific to buy Penumbra in deal valued at $14.5 billion

BSX

Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results

Jan 15, 2026, 7:00 AM EST - 2 months ago

Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results

Boston Scientific announces agreement to acquire Penumbra, Inc.

Jan 15, 2026, 7:00 AM EST - 2 months ago

Boston Scientific announces agreement to acquire Penumbra, Inc.

BSX

Penumbra, Inc. (PEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 4:06 AM EST - 2 months ago

Penumbra, Inc. (PEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Penumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 29, 2025, 4:30 PM EST - 2 months ago

Penumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference

Penumbra, Inc. (PEN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 3, 2025, 12:33 PM EST - 3 months ago

Penumbra, Inc. (PEN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 19, 2025, 4:30 PM EST - 4 months ago

Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference

Penumbra, Inc. (PEN) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 7:31 PM EST - 4 months ago

Penumbra, Inc. (PEN) Q3 2025 Earnings Call Transcript

Penumbra, Inc. Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 4 months ago

Penumbra, Inc. Reports Third Quarter 2025 Financial Results

Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism

Nov 3, 2025, 3:00 PM EST - 4 months ago

Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism

Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism

Oct 27, 2025, 9:00 AM EDT - 4 months ago

Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism

Penumbra, Inc. (PEN) Presents at Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 Transcript

Oct 27, 2025, 5:37 AM EDT - 4 months ago

Penumbra, Inc. (PEN) Presents at Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 Transcript

Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025

Oct 8, 2025, 4:30 PM EDT - 5 months ago

Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025

Penumbra, Inc. (PEN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 4:44 PM EDT - 6 months ago

Penumbra, Inc. (PEN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile

Sep 9, 2025, 9:00 AM EDT - 6 months ago

New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile

Penumbra, Inc. (PEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 3, 2025, 12:28 PM EDT - 6 months ago

Penumbra, Inc. (PEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Penumbra, Inc. Names Shruthi Narayan as Company President

Aug 27, 2025, 9:00 AM EDT - 7 months ago

Penumbra, Inc. Names Shruthi Narayan as Company President

Penumbra, Inc. to Present at Upcoming Investor Conferences

Aug 20, 2025, 4:30 PM EDT - 7 months ago

Penumbra, Inc. to Present at Upcoming Investor Conferences

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

Aug 7, 2025, 9:45 PM EDT - 7 months ago

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

ACLX BSX EW EXAS GH ISRG LLY

Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 30, 2025, 4:30 PM EDT - 8 months ago

Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference

Penumbra, Inc. (PEN) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 9:04 PM EDT - 8 months ago

Penumbra, Inc. (PEN) Q2 2025 Earnings Call Transcript

Penumbra, Inc. Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 4:05 PM EDT - 8 months ago

Penumbra, Inc. Reports Second Quarter 2025 Financial Results

Five years after COVID, pharma shares languish in US policy limbo

Jul 23, 2025, 9:57 AM EDT - 8 months ago

Five years after COVID, pharma shares languish in US policy limbo

ABBV ABT ALNY AZN EW LLY MRK

Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025

Jul 1, 2025, 4:30 PM EDT - 9 months ago

Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025

Penumbra: AI Meets Aspiration - Why The Stock Is A Structural Winner

Jun 26, 2025, 6:00 AM EDT - 9 months ago

Penumbra: AI Meets Aspiration - Why The Stock Is A Structural Winner

Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial

Jun 16, 2025, 9:00 AM EDT - 9 months ago

Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial

Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization

Jun 5, 2025, 9:00 AM EDT - 10 months ago

Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization

Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference

Apr 29, 2025, 4:30 PM EDT - 11 months ago

Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

Apr 29, 2025, 11:45 AM EDT - 11 months ago

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

ACLX ISRG MASI MCK NTRA TMO UNH

Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst

Apr 24, 2025, 3:27 PM EDT - 11 months ago

Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst

Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript

Apr 23, 2025, 8:15 PM EDT - 11 months ago

Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript

Penumbra, Inc. Reports First Quarter 2025 Financial Results

Apr 23, 2025, 4:05 PM EDT - 11 months ago

Penumbra, Inc. Reports First Quarter 2025 Financial Results

Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025

Apr 3, 2025, 4:30 PM EDT - 1 year ago

Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025

Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits

Apr 2, 2025, 9:00 AM EDT - 1 year ago

Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits

Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors

Feb 21, 2025, 4:05 PM EST - 1 year ago

Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors

smartkarma
smartkarma Mar. 6 at 8:03 PM
$PEN | Penumbra: STORM-PE Clinical Momentum & Physician Adoption—The Engine Behind Its Procedure Growth! "Penumbra, a company engaged in the innovative medical devices sector, has recently reported its financial performance for the third quarter of..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/penumbra-storm-pe-clinical-momentum-physician-adoption-the-engine-behind-its-procedure-growth
0 · Reply
ZacksResearch
ZacksResearch Mar. 2 at 1:18 PM
$PEN gets acquired! What does this mean for investors? 🤔 PEN announced a definitive agreement to be acquired by Boston Scientific for $374 per share, valuing the company at approximately $14.5 billion. The deal, subject to shareholder approval, is expected to close in 2026. See what this acquisition means for Penumbra's stockholders 👉 https://www.zacks.com/stock/news/2877227/pen-stock-up-following-q4-earnings-revenue-beat-margins-rise?cid=sm-stocktwits-2-2877227-body-35674&ADID=SYND_STOCKTWITS_TWEET_2_2877227_BODY_35674
0 · Reply
ZacksResearch
ZacksResearch Mar. 2 at 12:18 PM
$PEN pops after a clean Q4 beat — and margins are moving higher. 🚀 The company topped both earnings and revenue expectations in Q4, while also posting rising margins — a combo that signals improving operational strength, not just top-line noise. Beats + margin expansion? That’s how trends change. Get the full breakdown on what’s driving the move 👉 https://www.zacks.com/stock/news/2877227/pen-stock-up-following-q4-earnings-revenue-beat-margins-rise?cid=sm-stocktwits-2-2877227-teaser-35673&ADID=SYND_STOCKTWITS_TWEET_2_2877227_TEASER_35673
0 · Reply
cvmoney
cvmoney Feb. 27 at 9:51 PM
$PEN I want $370 by 3/20
0 · Reply
erevnon
erevnon Feb. 26 at 5:15 PM
Evercore ISI Group maintains Penumbra $PEN at Outperform and raises the price target from $340 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Estimize
Estimize Feb. 25 at 6:45 PM
$PEN reported 1.18 EPS and 385.39 revenue for Q4. http://www.estimize.com/intro/pen?chart=historical&metric_name=eps&utm_content=PEN&utm_me
0 · Reply
IN0V8
IN0V8 Feb. 20 at 9:27 PM
$PEN Canaccord Genuity cuts to hold from buy Canaccord Genuity raises target price to $374 from $359
0 · Reply
Subox
Subox Feb. 12 at 6:53 AM
$PEN $PEN drops like this are uncommon after an acquisition announce, does anyone know if one of the shareholders is maybe voting against the deal? A 15% premium is definitely not normal
0 · Reply
yaydeezie
yaydeezie Feb. 9 at 8:36 PM
$PEN Does anyone know what’s next for shareholders of $PEN in the $BSX acquisition? “Deal Structure and Shareholder Consideration Under the terms of the agreement, Penumbra shareholders will receive $374 per share, based on the volume-weighted average price of Boston Scientific stock over the ten trading days ending January 13. Shareholders may elect to receive either $374 in cash or 3.8721 shares of Boston Scientific stock, subject to proration.” https://news.bostonscientific.com/2026-01-15-Boston-Scientific-announces-agreement-to-acquire-Penumbra,-Inc
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 5 at 2:50 AM
$PEN Share Price: $339.88 Contract Selected: Jul 17, 2026 $340 Calls Buy Zone: $8.42 – $10.40 Target Zone: $15.34 – $18.75 Potential Upside: 72% ROI Time to Expiration: 162 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
phatsuit
phatsuit Jan. 30 at 3:32 PM
$PEN Go PEN!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 24 at 9:52 AM
$PEN RSI: 76.06, MACD: 14.4085 Vol: 19.78, MA20: 326.72, MA50: 308.21 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
IN0V8
IN0V8 Jan. 20 at 10:36 PM
$PEN Opportunity Canaccord Genuity cuts to hold from buy Canaccord Genuity raises target price to $374 from $359
0 · Reply
erevnon
erevnon Jan. 20 at 2:48 PM
Canaccord Genuity downgrades Penumbra $PEN from Buy to Hold and raises the price target from $359 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
jewell69
jewell69 Jan. 17 at 7:44 PM
$BSX ACQUIRING $PEN This morning, Boston Scientific announced a definitive agreement to acquire Penumbra (PEN, not covered), in a cash (73%) and stock (27%) transaction, for a total enterprise value of $14.5B. This total PEN acquisition price reflects a ~10x EV/R takeout multiple for scaled asset that delivered ~$1.4B in 2025 revenues. As evidenced by their 4Q25 numbers, Penumbra performance is clearly accelerating with ~22% revenue growth in the quarter and ~17% for the full 2025 year. By our rough math, once PEN turns organic, i.e. one-year post deal close, Penumbra adds about ~90bps to Boston's annual revenue growth rate.
0 · Reply
phatsuit
phatsuit Jan. 16 at 3:08 PM
$PEN Please continue
0 · Reply
PickAlpha
PickAlpha Jan. 16 at 1:28 PM
PickAlpha Morning Report - Company News: 2026.01.16 News Analysis - 1/4: Boston Scientific agrees to acquire Penumbra in ~$14.5bn cash-and-stock deal valued at $374 per share | View: Penumbra receives a defined 19.3% premium… $BSX $PEN $XLV
0 · Reply
erevnon
erevnon Jan. 16 at 11:57 AM
Truist Securities downgrades Penumbra $PEN from Buy to Hold and raises the price target from $370 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
free2dream
free2dream Jan. 15 at 8:30 PM
$PEN 14.5B on 1.3B sales ? $SRPT valued at $2B has higher sales
1 · Reply
WolfPack_Alerts
WolfPack_Alerts Jan. 15 at 6:52 PM
$PEN Cheers bulls!! Right within our exit target! $BSX $SPY
0 · Reply
If_ur_not_first_ur_last
If_ur_not_first_ur_last Jan. 15 at 5:15 PM
$BEAT $PEN come to beat next
0 · Reply